Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch in Canada in November

Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch in Canada in November

• The longest-lasting and most accurate1 continuous glucose monitoring (CGM) system authorized by Health Canada will offer people living with diabetes over the age of 18 up to 15.5 days of wear with fewer sensor changes.2
• Dexcom G7 15 Day will be publicly reimbursed for many eligible Canadians living with diabetes beginning in November.
• Private health plans that cover CGMs will be adding coverage for Dexcom G7 15 Day in November.

DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today that the Dexcom G7 15 Day Continuous Glucose Monitoring System (CGM) will be available in Canada beginning next month for adults 18 years and older living with diabetes. Offering up to 15.5 days of wear,2 Dexcom G7 15 Day combines industry leading sensor duration with best-in-class accuracy,1 giving Canadians living with diabetes more time between sensor changes and fewer interruptions to daily routines.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261028811764/en/

The Dexcom G7 15 Day Continuous Glucose Monitoring System (CGM) will be available in Canada beginning next month for adults 18 years and older living with diabetes.

Importantly, broad reimbursement will be in place starting in November, helping make this advancement accessible. Dexcom G7 15 Day will be publicly reimbursed for many eligible people living with type 1 and type 2 diabetes across Canada next month. In addition, most Canadians with private health plans that currently provide CGM coverage will soon have access to the latest Dexcom CGM technology.

“For people living with diabetes, staying aware of their glucose is part of everyday life. Our goal is to make that experience simple, seamless and intuitive,” said André Côté, Vice President and General Manager, Dexcom Canada. “With Dexcom G7 15 Day, we’re delivering the longest-lasting1 sensor on the market that does not compromise on accuracy and performance. We are also focusing on launching with significant public and private reimbursement already in place, helping more Canadians benefit from this technology right away.”

Designed to help people spend less time thinking about their CGM and more time living their lives, Dexcom G7 15 Day is the longest lasting1 and most accurate1 CGM system authorized by Health Canada, providing real‑time glucose readings for an industry leading 15.5 days.1,2 With an overall MARD of 8.0%,3 the system builds on the performance of Dexcom CGM which is clinically proven to lower A1C and increase time in range.4-8

Dexcom G7 15 Day sets a new standard in CGM technology that’s easy to use, painless to insert* and requires fewer sensor changes per month.

New with Dexcom G7 15 Day

• Longest lasting1 CGM system with up to 15.5 days2 of wear.
• Best-in-class accuracy with an overall MARD of 8.0%.1,3
• Easier glucose management with fewer monthly sensor changes and reduced waste.

Dexcom G7 features included with Dexcom G7 15 Day

• The only waterproof† CGMs available.2
• Direct to Apple Watch‡ connectivity, so you can leave your phone behind and still see your glucose numbers.
• 12-hour grace period to replace finished sensors for a more seamless transition between sessions.
• Innovative and simple mobile app with Dexcom Clarity integration to easily view glucose patterns, trends and statistics for meaningful conversations with your healthcare provider.§
• Ability to remotely share glucose numbers with caregivers and loved ones for added support and peace of mind.||,9
• Customizable alert settings for improved discretion and personalized diabetes management.

“Living with type 2 diabetes means there is always something to think about, whether it’s checking my glucose levels or making decisions about my health,” said Malcolm Kelly, Dexcom Warrior. “Having a CGM that lasts longer means one less thing to manage and fewer interruptions to my routine. Those small changes can make a big difference when you’re living with diabetes.”

Dexcom is working closely with its automated insulin delivery partners and looks forward to extending the launch to their customers shortly as they finalize integration.

To learn more about Dexcom G7 15 Day, visit Dexcom.com/dexcom-g7-15-day.

About Dexcom

Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in continuous glucose monitoring for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.

Dexcom. Discover what you’re made of. For more information, visit www.dexcom.com.

Category: IR

* 96% of patients reported mild/no pain. † The Dexcom G7 Sensor is waterproof and may be submerged under eight feet of water for up to 24 hours without failure when properly installed. ‡ Smart devices sold separately. To view a list of compatible devices, visit dexcom.com/compatibility. Compatible smartphone is required to pair a new Dexcom G7 sensor with a compatible Apple Watch. § An internet connection is required for users to send their glucose data to Dexcom Clarity via a compatible smart device: dexcom.com/compatibility. Healthcare providers will only be able to view a patient’s glucose data if the patient elects to share it with them through Dexcom Clarity. || Separate Dexcom Follow app and internet connection required. Users should always confirm readings on the Dexcom G7 app or receiver before making treatment decisions. 1 Dexcom, Data on File, 2026. 2 Dexcom G7 15 Day User Guide. 3 Garg SK, et al. Diabetes Technol Ther. 2025;27(6):413-502. 4 Beck RW, et al. JAMA. 2017;317(4):371-378. 5 Beck RW, et al. Ann Intern Med. 2017;167(6):365-374. 6 Martens T, et al. JAMA. 2021;325(22):2262-2272. 7 Oser TK, et al. N Engl J Med. 2026. doi: 10.1056/NEJMoa2608571. Epub ahead of print. 8 Welsh JB, et al. J Diabetes Sci Technol. 2024;18(1):143-147. 9 Polonsky WH, Fortmann AL. Diabetes Technol Ther. 2021;23(3):195-202.

Investor Contact:
Sean Christensen
sean.christensen@dexcom.com

Media Contact:
Nadia Conard
mediarelations@dexcom.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20261028811764/en/